Queen Mary University of London press release
Researchers at Queen Mary University of London have led the clinical development of the first non-integrase stand-transfer inhibitor (INSTI) single tablet treatment for HIV, amongst growing concern for the potential of widespread INSTI-resistance in resource limited settings. The results of the landmark phase 3 trial, published in The Lancet, show that the once-daily, single tablet combination of doravirine with islatravir is effective and safe treatment for HIV.
The new combination of doravirine plus islatravir has similar efficacy and safety to the integrase inhibitors. The study recruited far higher-than-usual numbers of women, older people, and racially minoritised adults for the trial – groups that are chronically under-represented in randomised trials for HIV treatments.
Read the full press release here.
Source : Queen Mary University of London
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.